Purpose of review To describe a new strategy that aimed to facilitate opioid prescription for better pain management.
INTRODUCTION
Cancer-related pain is a prevalent symptom experienced by almost 50% of patients in all stages of the disease and by more than 70% in advanced and terminal stages [1] . For advanced cancer, pain is moderate to severe in about 40-50% and very severe or excruciating in 25-30% of patients [2] .
Cancer pain management is a core component of palliative care. Guidelines to assist in the management of cancer pain were developed by the World Health Organization (WHO) more than 20 years ago [3] , based on these, other guidelines were developed [4] . The degree to which these guidelines have been effective in changing practice and improving patient care remains contentious.
However, many cancer pain patients worldwide do not have access to appropriate treatment, do not have access to pain-relieving medications, and undertreatment of pain persists despite efforts to provide clinicians with information regarding the use of analgesics [5] . There is evidence from surveys and observational studies that nearly one of two patients with cancer pain do not get adequate relief [6] . A survey of Human Rights Watch to healthcare workers in 40 countries about drug availability found that more than 3.5 million terminal cancer and HIV and AIDS patients die each year without access to adequate pain treatment, assuming that all opioids are used to treat this patient group [7 & ].
BARRIERS TO EFFECTIVE PAIN MANAGEMENT
Barriers to effective pain management exist in different countries around the world. Even in countries with abundant health resources, such as those in Western Europe [8] and the United States, with access to opioids in several formulations, inadequate training of healthcare professionals, regulatory barriers, and poor communication between physicians and patients often lead to significant undertreatment of pain. The problems in developing countries are more complex. Opioids are not available to the vast majority of patients in Latin America, Eastern Europe, Asia, and Africa [9] , and their accessibility is challenged by poverty, illiteracy, language barriers, long distances to health facilities, limited healthcare resources, and lack of training in pain management [10] . In addition, the fact that morphine and other strong analgesics are controlled medications has given rise to a host of problems related to their availability.
WHO has urged countries to put in place functioning supply and distribution systems, and to ensure that drug control measures do not unnecessarily impede their availability and accessibility [11] . Under the United Nations drug conventions, countries are obliged to ensure the 'adequate provision' of controlled medications while preventing their misuse or diversion [12] . Under international human rights law, countries are obliged to ensure the availability and accessibility of essential medications like morphine [13] .
RECOMMENDATIONS TO USE OPIOID ANALGESICS IN CANCER PAIN
According to the WHO ladder, opioid analgesics are the mainstay of cancer pain management for moderate and severe pain. As morphine and codeine are on the WHO Model List of Essential Medicines, countries must provide these medications as part of their core obligations under the right to health, regardless of whether they have been included on their domestic essential medicines lists [14] .
The European Association for Palliative Care (EAPC) [15 && ] do not specify a WHO step III opioid of first choice (morphine, oxycodone, or hydromorphone) for cancer pain treatment, but morphine has remained as the first-choice treatment because of its versatility (i.e. several routes of administration), clinical experience, availability, and cost rather than proven superiority.
Although other potent opioids have no advantage over morphine, there are differences in metabolism, side effects, and pharmacodynamics, which could be an advantage in some clinical situations. Transdermal fentanyl and buprenorphine are alternatives to oral opioids for patients unable to swallow, and, also with methadone, are safer in renal failure than morphine [16] .
Successful pain management requires adequate titration of the medication, so that analgesia is achieved with the least amount of adverse effects. Between 10 and 30% of patients treated with morphine do not have a successful outcome as a result of adverse effects, inadequate analgesia, or a combination of both [17] . Adverse effects of opioids, such as constipation and nausea, may limit the dosing of opioids and lead to early discontinuation and inadequate analgesia.
Constipation affects up to 87% of terminally ill people who are receiving opioids. There are strong recommendations that laxative prophylaxis for the prevention of constipation should be a priority when patients are starting opioid medication [18] . Laxatives can be broadly separated into two types: those that act by softening fecal matter and those that act through direct stimulation of peristalsis. The evidence to favor one laxative over another in palliative care is scarce. A combination of drugs with different modes of action is likely to be more effective in resistant constipation than a single agent. Few trials show that oral lactulose, polyethylene glycol or electrolyte solutions, and senna are effective in people with opioid-induced constipation [19] . Additionally, methylnaltrexone administered subcutaneously should be considered for the relief of opioid-induced constipation when traditional laxatives are not effective [20, 21] .
Nausea and vomiting occur in 15-40% of patients. Some healthcare professionals suggest using antiemetics for the prevention of nausea and vomiting whenever opioids are prescribed, but there is limited evidence to support this recommendation. Metoclopramide is generally recommended as the first-line therapy [22 & ]. Medications with central nervous system effects, such as haloperidol [23] , levomepromazine [24] , and cyclizine [25] , have been shown to be effective but may cause sedation and other adverse effects. The current evidence is too limited to give evidence-based recommendations for the use of antiemetics for opioid-induced nausea or vomiting in cancer patients. The evidence was also too limited to prioritize between symptomatic treatment and adjustment of the opioid treatment of moderate and severe pain. It also includes antiemetics and laxatives for the management of nausea and constipation [26] . However, the IAHPC List does not specify dosages or combinations of opioids, laxatives, and antiemetics which may be most well tolerated and effective in the prevention and treatment of chronic pain in patients who require initiation of strong opioids.
DEFINING AN OPIOID ESSENTIAL PRESCRIPTION PACKAGE
Recently, a working group of the IAHPC developed an opioid essential prescription package (OEPP) [27 & ] with the aim to facilitate opioid use, improve patient compliance, and reduce adverse effects, when initiating a prescription for the control of moderate-to-severe chronic pain.
A Delphi technique -a method for collecting and organizing informed opinions from a group of experts who are knowledgeable in a specialized area -was selected as the most appropriate tool for developing an essential package of prescriptions for the treatment of chronic pain. Using the Delphi method, a panel of experts are questioned about specific items or issues, usually involving several iterations (rounds) of a structured questionnaire [28] .
For the purpose of this study, a panel of 60 palliative care physicians were sampled from the IAHPC membership list to represent a range of countries based on the World Bank income classification (high, upper middle, lower middle, and low) and the WHO regional classification system (Africa, Americas, South East Asia, Europe, Eastern Mediterranean, and Western Pacific).
On the basis of IAHPC List of Essential Medicines for Palliative Care, physicians were asked to rank preferences of drug and dosing schedule for first-line opioid, antiemetic, and laxative for the treatment of adults with chronic pain due to cancer and other life-threatening conditions.
After two rounds, most of the participants agreed with the use of oral morphine 5 mg every 4 h as the first line of treatment. There was consensus that laxatives should always be given when opioid treatment is started. The combination of senna and docusate was the most preferred option to prevent constipation, but more than one-third of the participants reported having access difficulties to the combination, both in high-income and lowincome countries. Bisacodyl was chosen as the second option in treating constipation and has the advantage of being more accessible in most of the countries represented in this study. Metoclopramide was recommended as the first-line therapy in the management of opioid-induced nausea, but there was no consensus on dosing schedule.
The OEPP includes a recommend drug and dose of one opioid, one laxative, and one antiemetic for the initiation of opioid treatment in cancer pain and other life-threatening (see list below (a) metoclopramide, oral, 10 mg every 4 h or as needed.
CONCLUSION
The IAHPC OEPP was designed with the intention to facilitate the primary physicians to prescribe opioids in adult patients with moderate-to-severe chronic pain who require initiation of strong opioids.
Further work is needed to establish a recommended type and dose of laxative, as well as a dosing schedule for metoclopramide and to compare the OEPP with standard pain management approaches on outcomes such as pain prevalence and intensity, improvements in patient compliance, and reduction of adverse effects of opioids.
